Pharmaceuticals: unplanned interruptions generate high costs and create long delays

Setting up a production process for the pharmaceuticals sector is not a trivial undertaking.

Electrical power variations or even minor interruptions can neutralise tightly controlled biological working conditions and ruin an entire batch, resulting in irretrievable production losses.

The longer the event, the harder a pharmaceutical company’s profit margins are hit. Ensuring continuity of power supply is therefore of fundamental importance for this sector.

The European Copper Institute’s (ECI) Power Quality Survey demonstrates that the pharmaceuticals sector underestimates the impact of power interruptions and other Power Quality (PQ) incidents. It further illustrates that there is insufficient system design redundancy built into electrical power systems to guarantee this level of essential reliability.